Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient

Current Opinion in Nephrology and Hypertension

Volumn 20, Issue 5, 2011, Pages 465-470

  Schmid, Holger ^a   Schiffl, Helmut ^a   Lederer, Stephan R ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

chronic kidney disease; erythropoiesis stimulating agents; left ventricular hypertrophy; renal anemia

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN;

ANEMIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEMATOCRIT; HUMAN; HYPERTENSION; KIDNEY FAILURE; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANEMIA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE PROGRESSION; HEMATINICS; HEMOGLOBINS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 80051798372     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3283497057     Document Type: Review

References (46)

1. Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002;62:1402-1407.
2. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16:489-495. (Pubitemid 41725146)
3. Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 2009;4(Suppl 1):S79-S91.
4. Patel RK, Oliver S, Mark PB, et al. Determinants of left ventricular mass and hypertrophy in hemodialysis patients assessed by cardiac magnetic resonance imaging. Clin J Am Soc Nephrol 2009;4:1477-1483.
5. Paoletti E, Bellino D, Gallina AM, et al. Is left ventricular hypertrophy a powerful predictor of progression to dialysis in chronic kidney disease? Nephrol Dial Transplant 2011;26:670-677. This study analyzed the influence of baseline LVM index assessed by echocardiography in 144 patients with stage 3-4 CKD on progression to ESRD requiring dialysis, or death within 5 years. Using multivariate hazard analysis LVH proved to be the strongest predictor of the risk of progression to dialysis in nondiabeticCKD, especially among patients with less advanced renal dysfunction. This important finding emphasizes the impact of LVH on renal and general outcome in CKD patients and has to be substantiated in the future.
6. Foley RN, Curtis BM, Randell EW, Parfrey PS. Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol 2010;5:805-813. The authors analyzed baseline and serial echocardiograms of 596 incident HD patients and identified higher time-integrated SBPand cause of ESRD as independent predictors of increase in LVM index in patients without LVH at baseline. This randomized, controlled large-scale study underscores the complexity of progressive concentric LVH in ESRD patients that is partly explained by hypertension but not by a wide array of potential other risk factors, including anemia.
7. Nardi E, Palermo A, Mule G, et al. Impact of type 2 diabetes on left ventricular geometry and diastolic function in hypertensive patients with chronic kidney disease. J Hum Hypertens 2011;25:144-151. This well performed case-control study on 288 white patients with hypertension and CKD demonstrated that presence of diabetes is associated with increased left-ventricular wall thicknesses and concentric left-ventricular remodeling, and that left-ventricular geometry affects early diastolic relaxation. Further studies have now to clarify the role of additional associated factors and underlying mechanisms in hypertensive, diabetic heart disease.
8. Levin A, Singer J, Thompson CR, et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996;27:347-354. (Pubitemid 26075843)
9. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-134. (Pubitemid 29318806)
10. Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000;35:250-256. (Pubitemid 30070847)
11. Pascual J, Teruel JL, Moya JL, et al. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 1991;35:280-287.
12. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-590. (Pubitemid 28385655)
13. Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000;58:1325-1335.
14. Parfrey PS, Foley RN, Wittreich BH, et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005;16:2180-2189. (Pubitemid 41716451)
15. Macdougall IC, Temple RM, Kwan JT. Is early treatment of anaemia with epoetin-alpha beneficial to predialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial. Nephrol Dial Transplant 2007;22:784-793. (Pubitemid 46351686)
16. Drueke TB, Locatelli F, Clyne N, et al., CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084. (Pubitemid 44749316)
17. Eckardt KU, Scherhag A, Macdougall IC, et al. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J Am Soc Nephrol 2009;20:2651-2660.
18. Singh AK, Szczech L, Tang KL, et al., CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098. (Pubitemid 44749317)
19. Szczech LA, Barnhart HX, Sapp S, et al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int 2010;77:239-246. This secondary analysis of CHOIR compared outcomes among subgroups of patients with greater mortality risk and observed no increased clinically apparent risk associated with higher Hb targets in patients with diabetes or heart failure. This important finding challenges the impact of comorbidities on ESA-treated CKD patients, underscores the need for dedicated trials and potentially argues for more individualized ESA treatment in different subpopulations.
20. Pfeffer MA, Burdmann EA, Chen CY, et al., TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032.
21. Locatelli F, Aljama P, Canaud B, et al., Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant 2010;25:2846-2850.
22. Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010;153:23-33. This comprehensive meta-analysis of 27 trials summarized recent evidence that higher Hb targets in CKD increased the risk for stroke, hypertension, and vascular access thrombosis. In addition, the authors tried to sensitize the renal community that mechanisms for harm are unclear and meta-analysis of individual-patient data and trials on fixed ESA doses are urgently needed to elucidate these mechanisms.
23. Strippoli GF, Clinical Evaluation of the DOse of Erythropoietins Study Group (C. E. DOSE). Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C. E. DOSE) trial protocol. Trials 2010;11:70.
24. Eckardt KU, Kim J, Kronenberg F, et al. Hemoglobin variability does not predict mortality in European hemodialysis patients. J Am Soc Nephrol 2010;21:1765-1775. In the context of conflicting results regarding the association of Hb variability with patient outcomes, this cutting-edge analysis concluded that although Hb variability is common in HD patients, it does not independently predict mortality in an European cohort.
25. Kainz A, Mayer B, Kramar R, Oberbauer R. Association of ESA hypo-respon-siveness and haemoglobin variability with mortality in haemodialysis patients. Nephrol Dial Transplant 2010;25:3701-3706. This study analyzed ESA response in European maintenance hemodialysis patients and identified ESA hyporesponsiveness as an important risk factor for increased mortality. Of particular note, the authors were able to demonstrate that in hyporesponders mortality was not associated with ESA dose or Hb range, whereas in ESA responders dose equivalents greater than 16 000 units per week were associated with increased mortality, a finding that needs further clarification.
26. Lau JH, Gangji AS, Rabbat CG, Brimble KS. Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial. Nephrol Dial Transplant 2010;25:4002-4009. Demonstrating an independent association of rapid Hb rises and ESA dose increases with mortality in HD patients, this study could implicate future randomized controlled trials evaluating different ESA dosing strategies in response to individual patient ESA responsiveness.
27. Solomon SD, Uno H, Lewis EF, et al., Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010;363:1146-1155. This secondary analysis of TREAT underscored the finding that a poor initial hematopoietic response to ESA treatment is associated with an increased risk of death and cardiovascular events. These data should alert clinicians that consideration of the recommended target Hb alone could be a dangerous simplification of treatment strategy.
28. Merchant ML, Gaweda AE, Dailey AJ, et al. Oncostatin M receptor β and cysteine/histidine-rich 1 are biomarkers of the response to erythropoietin in hemodialysis patients. Kidney Int 2011;79:546-554. This pioneer work including peptidomic analyses and mass spectrometry of patient sera identified candidate biomarkers of both responsiveness and resistance to ESAs in HD patients. Future research has now to substantiate the clinical practicability of these biomarkers.
29. Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001;161:1207-1216. (Pubitemid 32691517)
30. Muntner P, Judd SE, Krousel-Wood M, et al. Low medication adherence and hypertension control among adults with CKD: data from the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. Am J Kidney Dis 2010;56:447-457. This large-scale study demonstrated low antihypertensive medication adherence as an important barrier to achieve sufficient BP control in hypertensive patients. Future studies in this field have now to develop improved and novel methods of measuring medication adherence, as no true gold standard exists.
31. Khosla N, Kalaitzidis R, Bakris GL. The kidney, hypertension, and remaining challenges. Med Clin North Am 2009;93:697-715.
32. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173. This secondary analysis of an outstanding trial showed that initial antihypertensive therapy with benazepril and amlodipine was able to slow the progression of nephropathy. This finding will probably affect future guidelines for hypertension treatment as the effect of a combination therapy including a RAAS inhibitor has been rarely comparatively studied with regard to renal protection.
33. Appel LJ, Wright JT Jr, Greene T, et al., AASK Collaborative Research Group. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010;363:918-929. This important long-term trial found that in black patients with hypertensive CKD intensive BP control as compared with standard BP control had no effect on kidney disease progression. Current discussion in the renal community indicates that these findings should be interpreted with caution, as the differences in disease progression among patients with CKD with and without proteinuria are yet not completely understood.
34. Agarwal R. Volume-associated ambulatory blood pressure patterns in hemodialysis patients. Hypertension 2009;54:241-247.
35. Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009;373:1009-1015.
36. Inrig JK, Patel UD, Toto RD, Szczech LA. Association of blood pressure increases during hemodialysis with 2-year mortality in incident hemodialysis patients: a secondary analysis of the Dialysis Morbidity and Mortality Wave 2 Study. Am J Kidney Dis 2009;54:881-890.
37. Miller AB, Reichek N, St John Sutton M, et al. Importance of blood pressure control in left ventricular mass regression. J Am Soc Hypertens 2010;4:302-310. This crucial study concluded that achievement of targeted BP control is more important than treatment regimen in achieving left-ventricular mass reduction. Of note, this double-blind, parallel-group design study examined effects of combination antihypertensive therapy in the non-CKD population.
38. Schmitt KE, Edie CF, Laflam P, et al. Adherence to antihypertensive agents and blood pressure control in chronic kidney disease. Am J Nephrol 2010;32:541-548.
39. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension 1997;29:641-650. (Pubitemid 27074731)
40. Parfrey PS, Foley RN, Harnett JD, et al. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996;11:1277-1285. (Pubitemid 26241416)
41. Harnett JD, Kent GM, Barre PE, et al. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 1994;4:1486-1490.
42. Ok E, Duman S, Asci G, et al. On behalf of the 'Long Dialysis Study Group'. Comparison of 4-and 8-h dialysis sessions in thrice-weekly in-centre haemodialysis: a prospective, case-controlled study. Nephrol Dial Transplant 2010 [Epub ahead of print].
43. Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs. conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. J Am Med Assoc 2007;298:1291-1299. (Pubitemid 47443343)
44. Siddiqi L, Prakken NH, Velthuis BK, et al. Sympathetic activity in chronic kidney disease patients is related to left ventricular mass despite antihypertensive treatment. Nephrol Dial Transplant 2010;25:3272-3277. This pilot study highlighted a positive relationship between sympathetic hyperactivity and increased LVM that was independent of BP. Future research has now to substantiate this finding before potential benefits of additional sympatholytic therapy should be tested in CKD patients.
45. Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009;119:2545-2552.
46. Kanbay M, Nicoleta M, Selcoki Y, et al. Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol 2010;5:1780-1786.